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Background: Many patients with chronic hepatitis C have been treated with interferon (IFN) therapy in Japan,
especially after the introduction of subsidies for medical expenses in 2008. However, its performance and outcome
have never been evaluated. Therefore, a nationwide, mail-based, retrospective cohort study was conducted.
Methods: Regional disparities in the demographic features, treatment performance, and virological response were
evaluated using an intent-to-treat design. The participating prefectures were classified into nine regions from north
to south (Hokkaido/Tohoku, Kanto, Shin-etsu, Hokuriku, Tokai, Kinki, Chugoku, Shikoku, and Kyushu). Multivariate
logistic regression analysis was performed to select predictive factors for treatment performance and outcome.
Results: From December 2009 to May 2013, 16,854 patients with chronic hepatitis C were registered from 37
prefectures in Japan (median age: 60 years; 50.4 % male; 74.8 % IFN-naïve; HCV genotype [1 or 2]/viral load [high
(≥5 log IU/mL) or low (<5 log IU/mL)]: 1/high = 58.2 %, 1/low = 5.2 %, 2/high = 27.3 %, 2/low = 7.5 %; 83.4 % treated
with peginterferon-α and ribavirin). Mean age, proportion of elderly patients (≥65 years), male sex, IFN-experienced,
and HCV genotype were significantly different among the nine regions (all P < 0.001). Regional disparities were
independently selected as one of the predictive factors for treatment performance and outcome in patients treated
with peginterferon-α and ribavirin, which revealed two regions that required further investigation.
Conclusions: Regional disparities still exist in IFN therapy, and are strongly associated with treatment performance
and outcome. Since the accessibility to medical resources for individual patients seemed to be different among the
nine regions, public health actions should be focused on how to construct and properly manage consultation
networks between base hospitals and local clinics, especially in those regions with low population density.
Keywords: Treatment performance, Treatment outcome, Peginterferon-α, Ribavirin, Subsidy policyBackground
There are 130–150 million people infected with hepatitis
C virus (HCV) worldwide, and 350,000–500,000 patients
die of HCV-related liver diseases annually (e.g., liver cir-
rhosis or hepatocellular carcinoma) [1]. Standard treatment
for chronic hepatitis C (CHC) has been peginterferon-α
and ribavirin (P/R), and the sustained virological response
(SVR) rate has remained at 50 %, in difficult-to-treat cases* Correspondence: nmasaki0808@gmail.com
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creativecommons.org/publicdomain/zero/1.0/of HCV genotype 1 and high viral load [2]. The introduc-
tion of protease inhibitors, such as boceprevir [3, 4], tela-
previr [5, 6], or simeprevir [7, 8] could improve the SVR
rate up to 75–85 % in interferon (IFN)-naïve cases. Fur-
thermore, the era of IFN-free treatment with oral-only dir-
ectly acting antivirals (DAAs) has just become a reality
with SVR rate > 90 % [9–11].
Standardized performance and outcome of antiviral
therapy are essential to eradicating HCV, which could
significantly decrease the risk of progression to liver dis-
eases (e.g., liver cirrhosis and hepatocellular carcinoma).
For this purpose, the Japanese government and 47 local
governments started nationwide strategies from Januaryrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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tures, authorized later by the Basic Act on Hepatitis
Measures (Act No. 97, December 4, 2009) [12]. Almost
concurrently, subsidies for antiviral treatment (e.g., IFN
therapy for patients infected with hepatitis B virus [HBV]
or HCV, or nucleoside analogs for those infected with
HBV) were introduced to provide more patients with a
higher chance of virological response. For example, the
total medical expenses for 48 weeks of standard care for
a patient with CHC could reach 23,930 USD for
peginterferon-α2a (180 μg = 278.3 USD) and ribavirin
(800 mg = 31.5 USD) combination therapy. The patient
will have to pay 600 USD for P/R every month, as the
average coverage of health insurance is 70 % in Japan.
With the aid of this subsidy policy, the patients will only
have to pay ~100–200 USD monthly according to their
taxable income. More than 117,000 patients benefited
from this subsidy policy during the initial 4 years (April
2008 to March 2012). The fact that the substantial
amount of public money was allocated for the subsidy
policy urged us to perform a nationwide retrospective
study to evaluate whether the performance and out-
come of IFN therapy have been standardized through-
out Japan.
Methods
The outlines of the study
The Hepatitis Information Center of the National Center
for Global Health and Medicine (Chiba, Japan) started a
retrospective cohort study to construct the Japanese
Interferon Database in December 2009. All 47 prefectural
governments were invited to join this project. Currently,
37 prefectures have been participating and sending data to
the Hepatitis Information Center. The standard duration
of P/R therapy was 48 weeks and 24 weeks for genotype 1
and non-genotype 1, respectively, and the final therapeutic
outcome was determined 24 weeks after the treatment
period, according to the guidelines of the American Asso-
ciation for the Study of Liver Diseases [13] and the Japan
Society of Hepatology [14]. The local governments had
the application forms submitted by each patient, in
which the genotype or serotype of HCV, viral load,
scheduled date of treatment, and demographic features
of the patients were described. Therefore, the requests
to draw up the reports on therapeutic outcomes were
made in a timely manner to the relevant doctors by the
local governments.
Most of the enrolled patients were treated by P/R with
weekly administration of peginterferon-α2a (Pegasys;
Chugai Pharmaceutical, Tokyo, Japan) and daily riba-
virin (Copegus; Chugai Pharmaceutical), or weekly
peginterferon-α2b (Pegintron; MSD, Tokyo, Japan) and
daily ribavirin (Rebetol; MSD). The dose of peginterferon-
α2a, regardless of the patient’s body weight, was 180 μg.However, the dose of peginterferon-α2b was adjusted
based on the patient’s body weight as follows: patients
weighing ≤45 kg, >45 kg and ≤60 kg, >60 kg and ≤75 kg,
>75 kg and ≤90 kg, and >90 kg were given 60 μg, 80 μg,
100 μg, 120 μg, and 150 μg of peginterferon-α2b weekly,
respectively. Patients weighing ≤60 kg, >60 kg and ≤80 kg,
and >80 kg were given 600 mg, 800 mg, and 1000 mg
of ribavirin daily, respectively. Dose modification of
peginterferon-α or ribavirin was based on the manufac-
turers’ recommendations.
The format of the reports was unified and the demo-
graphic features of the patients included sex, date of birth,
scheduled treatment period, previous history of IFN ther-
apy, clinical and/or histological diagnosis, and IFN regi-
men. The data for virological markers, including viral load
and serum transaminases levels, were collected before
treatment, at cessation of treatment, and at final analysis.
Peripheral platelet counts during the pre-treatment period
were included. Determination of serotype and/or genotype
(if possible) was a prerequisite for the standard treatment
of chronic HCV infections in Japan. HCV RNA was deter-
mined by quantitative real-time polymerase chain reaction
(COBAS AmpliPrep/COBAS TaqMan HCV Test; Roche
Molecular Systems, Pleasanton, CA, USA). A high viral
load was considered ≥5.0 log10 IU/mL HCV RNA. To-
gether with these demographic features, information re-
garding virological outcome, treatment performance
(i.e., accomplishment or withdrawal), reasons for treat-
ment withdrawal (i.e., severe adverse events or other
unrelated events), and personal information including
patient identification and written informed consent were
reported to the local governments. Thereafter, the data
without personal information were sent to the Hepatitis
Information Center with assigned temporary identifica-
tions to maintain anonymity in future references.
To analyze possible regional disparities in treatment
performance and virological response, the 37 prefectures
participating in this study were classified into nine re-
gions from north to south as follows (numbers in paren-
theses denote the number of participating prefectures in
each region): Hokkaido/Tohoku (6), Kanto (4), Shin-etsu
(3), Hokuriku (3), Tokai (3), Kinki (6), Chugoku (4),
Shikoku (3), Kyushu (5) (Fig. 1).
Virological response
Virological response was assessed by each doctor in
charge according to the standard criteria described below.
SVR was defined as undetectable HCV RNA levels in
serum 24 weeks after cessation of treatment, while transi-
ent virological response (TVR) was defined as reappear-
ance of HCV RNA in serum following undetectable HCV
RNA at cessation of treatment. Nonvirological response
(NVR) was defined as <2 log-unit decline in serum HCV
RNA levels from the pre-treatment baseline value within
Fig. 1 A map showing nine regions of Japan. The percentages of CHC cases for each region are shown in the small inset. The three biggest
cities, Tokyo, Osaka and Nagoya are located in Kanto, Kinki and Tokai, respectively
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treatment initiation. Patients who were withdrawn from
treatment because of the presence of serum HCV RNA at
24 weeks of therapy, or viral breakthrough, or who were
lost during treatment or follow-up were included in the
intent-to-treat analysis.
Evaluation of liver fibrosis
Since liver biopsy has not been regularly performed in
recent clinical settings, a simple non-invasive index (Fi-
brosis-4 [FIB-4] index), which correlates well with hep-
atic fibrosis as determined by liver biopsy [15], was used
to evaluate the extent of liver fibrosis. The FIB-4 index
was used for multivariate logistic regression analysis, in-
stead of clinical diagnoses.
Ethics statement
The study protocol complied with the Helsinki Declar-
ation and was approved by the Ethics Committee of the
National Center for Global Health and Medicine, Japan
(#738; October 1, 2009). Written informed consent was
obtained from the patients prior to enrollment.
Statistical analysis
Continuous variables were expressed as median and inter-
quartile ranges, unless otherwise specified, and compared
using the Mann–Whitney U test or Kruskal–Wallis ana-
lysis. Categorical variables were compared using Pearson’sχ2 test or Fisher’s exact test. The demographic features of
the patients were compared among the nine regions
using Kruskal–Wallis analysis or Pearson’s χ2 test.
Multivariate analysis was performed using a simultan-
eous, non-stepwise, logistic regression analysis, with all
examined parameters, regardless of the univariate ana-
lysis results. All P-values were two-tailed, and P < 0.05
was considered statistically significant. Data analyses
were performed using IBM SPSS Statistics for Windows,
Version 20.0 (IBM Corp., Armonk, NY, USA).
Results
Patient demographics
From December 2009 to May 2013, 17,169 reports were
sent to the Hepatitis Information Center. The etiology of
chronic liver diseases was HBV alone (n = 315), HCV
alone (n = 16,838), and co-infection with HBV and HCV
(n = 16). Hence, 98.2 % of the reports (n = 16,854) were
HCV related and further analyses were confined to pa-
tients with HCV infection. The percentages of reports
from each region are shown in the small inset of Fig. 1.
The age distributions of this cohort at every decade were
as follows: <9 years (n = 3); 10–19 years (n = 24); 20–29
years (n = 310); 30–39 years (n = 831); 40–49 years (n =
2141); 50–59 years (n = 4916); 60–69 years (n = 6625);
70–79 years (n = 1915); >80 years (n = 45); and unknown
(n = 44). The median age was 60.0 years (interquartile
range, 52.0–66.0 years). Demographic features (i.e., mean
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IFN treatment, and HCV genotype distribution) differed
significantly among the nine regions (P < 0.001; Table 1).Treatment performance and outcome in patients treated
by peginterferon-α and ribavirin
About 83.4 % (n = 14,061) of the patients were treated
with P/R. Therefore, further analyses were restricted to
this regimen to clarify the current treatment perform-
ance and outcome in Japan. The average percentage of
treatment accomplishment in the P/R-treated cohort was
82.8 %. The percentage of treatment accomplishment was
higher than the average in five regions (i.e., Kanto, Hokuriku,
Tokai, Chugoku, and Kyushu) and lower than the average in
the other four (P = 0.009) (Fig. 2). SVR, TVR, NVR, and
undetermined response differed significantly among the nine
regions (Fig. 3, P < 0.001). Such regional disparities were
more clearly demonstrated by stratification with the HCV
genotypes and viral loads. As shown in Fig. 4, regional
disparities regarding treatment performance were
detected in the genotype 2 subgroup (P = 0.018, with
Bonferroni method), especially with high viral load
(P = 0.036), but not in genotype 1. However, regional
disparities regarding treatment outcome were con-
firmed in the subgroups with high viral load, regardless
of HCV genotypes.Predictive factors for treatment performance
To determine the factors associated with treatment accom-
plishment with P/R, univariate analysis was performed
(Table 2). Treatment accomplishment rate was significantly
lower in the elderly group (77.2 vs. 85.1 % [<65 years]),
IFN-experienced cases (81.7 vs. 83.1 % [IFN naive]),
genotype 1 group (79.0 vs. 91.1 % [genotype 2 + 3]), and
high viral load group (82.7 vs. 85.3 % [low viral load]).
Higher levels of serum aspartate aminotransferase
(AST), FIB-4 index, and lower platelet counts were
significantly associated with treatment withdrawal. In
addition, treatment accomplishment rate gradually de-
creased in patients whose treatment was initiated in
2009 and later (i.e., 85.2 % [-2008], 82.8 % [2009], 80.2 %
[2010-]; P < 0.001).
We found that treatment accomplishment rate differed
among the nine regions in the entire P/R-treated cohort
(P = 0.009, Fig. 2), especially in the genotype 2 subgroup
with high viral load (Fig. 4, upper panel), and was closely
associated with treatment outcome (i.e., 95.8, 84.8 and
45.8 % in SVR, TVR and NVR, respectively). According
to the multivariate and simultaneous logistic regression
analysis (Table 2), the following six factors independently
contributed to treatment withdrawal: old age, genotype 1,
high serum AST levels, high FIB-4 index, later year of
starting treatment, and region. Treatment accomplishmentrate was lower in Hokkaido/Tohoku and Shikoku, and
higher in Tokai among 9 regions.
Predictive factors for treatment outcome
To evaluate factors associated with SVR in P/R therapy,
univariate analysis was performed (Table 3). The SVR
rates were lower in female patients (54.8 vs. 63.6 % [male
patients]), elderly patients (47.3 vs. 64.1 % [<65 years]),
IFN-experienced cases (49.7 vs. 62.4 % [IFN-naive]),
genotype 1 group (48.9 vs. 80.8 % [genotype 2 + 3]), and
high viral load group (57.7 vs. 80.2 % [low viral load]).
Serum AST and alanine aminotransferase (ALT) levels,
peripheral platelet counts, and FIB-4 index were signifi-
cantly different between SVR and non-SVR. In addition,
SVR rates were increased in patients who had initiated
treatment in 2009 and later (i.e., 56.8 % [-2008], 59.0 %
[2009], and 60.6 % [2010-]; P = 0.019).
We were able to demonstrate that the treatment out-
come was significantly different among the nine regions
in the entire P/R-treated cohort (P < 0.001) and in the
subgroups with high viral load, regardless of HCV geno-
types (Fig. 4, lower panel). Furthermore, SVR rates were
closely associated with treatment performance (i.e., 67.7
and 15.5 % in treatment accomplishment and withdrawal,
respectively; data not shown). According to the multivari-
ate and simultaneous logistic regression analysis (Table 3),
most of the factors independently contributed to non-SVR
(i.e., female sex, old age, experienced IFN treatment, geno-
type 1, high viral load, low serum ALT levels, low periph-
eral platelet counts, high FIB-4 index, and region). SVR
rates in patients who had initiated treatment in 2010 and
later were higher during the periods examined. In addition,
SVR rates were significantly lower in Hokkaido/Tohoku
and Shikoku among 9 regions.
Discussion
In this study, regional disparities in the demographic fea-
tures of IFN-treated patients (i.e., age, sex, history of
IFN treatment, and prevalence of HCV genotypes) in
Japan have been demonstrated for the first time. Fur-
thermore, regional disparities in treatment accomplish-
ment and outcome of standard treatment with P/R were
also observed. Regional disparities and other known pre-
dictive factors were independently associated with treat-
ment performance and outcome. The inconsistent increase
in treatment withdrawal in patients who started treatment
later in the year could be explained by the gradual spread
of concepts related to response-guided therapy [16], which
is chiefly based on cost effectiveness, especially in treat-
ment of hard-to-cure patients [17].
It should be emphasized that the rates of treatment
accomplishment and SVR in the Hokkaido/Tohoku and
Shikoku regions were significantly lower among 9 regions.
A strong correlation between SVR rate and treatment
Table 1 Demographic features of patients with chronic hepatitis C treated with interferon (IFN) in nine regions of Japan
All Hokkaido/Tohoku Kanto Shin-etsu Hokuriku Tokai Kinki Chugoku Shikoku Kyushu P-value
n 16854 2055 1142 781 1046 1170 3565 2599 716 3780
Age (years)a 57.9 ± 10.9 56.9 ± 10.5 56.5 ± 11.3 59.4 ± 10.1 60.2 ± 9.3 58.7 ± 10.4 57.3 ± 11.6 59.3 ± 10.7 57.8 ± 10.1 57.5 ± 11.1 <0.001b
The elderly
(≥65 years) (%)
30.2 26.1 24.9 34.4 35.3 32.5 29.9 34.9 26.7 28.7 <0.001c
Gender
male (%)
50.4 50.6 53.3 46.7 44.3 48.8 51.5 49.7 54.6 51.2 <0.001c
IFN-experienced
cases (%)

























aAge is shown as mean ± standard deviation
bKruskal–Wallis analysis
cPearson’s χ2 test













Fig. 2 Regional disparities in treatment performance in patients with chronic hepatitis C treated by peginterferon-α and ribavirin (P/R). As for the
rates of treatment accomplishment, the average of the P/R-treated cohort was 82.8 %, and was higher than the average in five regions (Kanto,
Hokuriku, Tokai, Chugoku, and Kyushu), and lower than average in the other four. The rates of treatment accomplishment differed significantly
among the nine regions (P = 0.009)
Fig. 3 Regional disparities in treatment outcome in patients with chronic hepatitis C treated by peginterferon-α and ribavirin (P/R). In the entire
P/R-treated cohort (n = 14,061), the treatment outcome was as follows: the rates of sustained virological response (SVR), transient virological
response (TVR), non-virological response (NVR), and undetermined response were 56.7 %, 20.6 %, 18.6 %, and 4.1 %, respectively. There were
regional disparities among the nine regions in treatment outcome (P < 0.001)
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Fig. 4 Summary of regional disparities in treatment performance and outcome, in subgroups stratified with genotypes and viral loads of hepatitis
C virus (HCV). a Treatment performance. Regional disparities were detected in the genotype 2 subgroup (P = 0.018), especially with high viral load
(P = 0.036), but not in genotype 1. b Treatment outcome. Regional disparities were confirmed in the subgroups with high viral load, regardless of
HCV genotypes. The P-values were adjusted with the Bonferroni method for the number of strata
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file 1: Figure S1) suggests the presence of factors that in-
fluence treatment accomplishment, leading to non-SVR,
in these two regions. Although the percentage of IFN-
experienced cases in Shikoku was higher than in other
regions, a history of IFN treatment was not chosen as a
predictive factor for treatment accomplishment by multi-
variate analysis. The reasons for treatment withdrawal
were divided into two categories: severe adverse events,
and unrelated incidents. The proportions of these two cat-
egories were ~60 and ~40 %, respectively, throughout
Japan, and there was no regional difference among the
nine regions (Additional file 2: Figure S2). However, in the
category of unrelated incidents, the proportion with “poor
response to P/R, according to criteria for response-guided
therapy” differed among the nine regions (P = 0.019;
Additional file 3: Figure S3). In Hokkaido/Tohoku, the
proportion was the lowest among the nine regions,
which suggests the presence of the other factors pecu-
liar to this region. Treatment accomplishment rate and
SVR rate were not associated with the proportion of eld-
erly patients in the P/R-treated cohort (Additional file 4:
Figure S4 and Additional file 5: Figure S5) or the numbersof specialists in hepatology, designated by the Japan
Society of Hepatology, per 100,000 people in each re-
gion (Additional file 6: Figure S6 and Additional file 7:
Figure S7). Therefore, we need to consider another
possibility such as limited accessibility to medical re-
sources, particularly in the regions with low population
density. Hokkaido and Tohoku are the regions with the
lowest population density in Japan (Additional file 8:
Figure S8). Therefore, consultation networks between
base hospitals and local clinics should be constructed
and properly managed by public health actions, espe-
cially in those regions.
Many findings similar to our study have recently been
accumulated by public health policies regarding regional
disparities in the treatment outcome of acute illness and
malignant disorders. O’Connor et al. have reported that
substantial geographic variation exists in the treatment
of patients with acute myocardial infarction in the US,
probably resulting from underuse of therapies with proven
benefit in local clinical practices [18]. Gentry et al. recently
proposed that geographic disparities in the 90-day trans-
plant rates and waiting-list death rates for liver transplant-
ation in the US could be reduced by redistricting based on
Table 2 Factors associated with withdrawal of peginterferon-α and ribavirin treatment in chronic hepatitis C patients
Groups Univariate analysis Multivariate analysis
Factors Treatment accomplishment Treatment withdrawal Coefficient P-value B Odds ratio 95 % C.I.
Gender (Male/Female) 5824/5766 1184/1226 1.004 0.325 0.000 1.000 0.911–1.099
Age (≥65 years/<65 years) 3146/8423 930/1473 127.536 <0.001 −0.326 0.722 0.651–0.800
History of IFN treatment
(naive/experienced)
8463/2928 1716/657 4.005 0.047 0.032 1.033 0.929–1.147
Genotype (1/2 + 3) 7326/4050 1953/397 311.818 <0.001 −1.007 0.365 0.324–0.412
Viral load (high/low) 10713/817 2248/141 4.327 0.038 −0.091 0.913 0.750–1.112
Pre-AST (U/L)a 43 [30–68] (n = 11511) 48 [34–73] (n = 2385) <0.001 0.001 1.001 1.000–1.003
Pre-ALT (U/L)a 51 [31–87] (n = 11517) 52 [34–81] (n = 2384) 0.517
Pre-PLT (x104/μL) 16.0 [13.0–20.0] 15.0 [12.0–19.0] <0.001 0.001 1.001 0.990–1.013
(n = 11381) (n = 2349)
FIB-4 index 2.26 [1.48–3.42] 2.84 [1.84–4.28] <0.001 −0.125 0.882 0.850–0.916
(n = 11349) (n = 2341)
Year of starting
treatment
– 2008 4624 804 Reference
2009 2845 588 45.561 <0.001 −0.219 0.803 0.710–0.909
2010– 4119 1015 −0.496 0.609 0.545–0.680
Region Hokkaido/Tohoku 1404 318 −0.242 0.785 0.666–0.925
Kanto 793 124 0.180 1.197 0.958–1.497
Shin-etsu 528 114 0.020 1.020 0.802–1.297
Hokuriku 717 148 0.036 1.037 0.838–1.283
Tokai 814 145 20.418 0.009 0.231 1.260 1.019–1.558
Kinki 2385 544 −0.048 0.953 0.827–1.098
Chugoku 1890 380 0.006 1.006 0.864–1.172
Shikoku 476 115 −0.240 0.787 0.619–0.999
Kyushu 2589 522 Reference
The values of pre-AST, pre-ALT, pre-PLT, and FIB-4 index are shown as median [interquartile range]
aSince pre-AST and pre-ALT were closely correlated (r = 0.872; P < 0.001), only pre-AST was included in multivariate analysis. Significant factors by multivariate ana-
lysis are shown in bold. The patients whose treatment performance could not be determined were excluded from this analysis (n = 55)
ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; C.I., Confidence interval; FIB-4, Fibrosis-4; IFN, Interferon; PLT, Platelets; SVR, Sustained
virological response
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found that breast cancer mortality rates, which varied
among counties in Middle Tennessee, correlated with
additional risk factors (i.e., mammography screening and
socioeconomic status) and proposed resources to reduce
breast cancer mortality [20]. In contrast, information re-
garding regional disparities for the treatment of CHC with
P/R is limited. In the IDEAL Study, no significant differ-
ences were detected in the various metrics of quality and
site performance (i.e., adherence, adverse events, treat-
ment withdrawal, on-treatment virological response, and
SVR) between 76 academic-based and 42 community-
based centers in the US [21]. Based on these previous
studies, further evaluations of local clinical practices
should be mandatory to explore the reasons for regional
disparities in treatment and outcome of P/R therapy in
Japan, especially in the two regions identified in our study,
Hokkaido/Tohoku and Shikoku. Again, access to medicaltreatment would be a serious burden on patients who are
company employees or residents in the regions with low
population density, partly because the self-injection of
peginterferon-α has not yet been approved by the Pharma-
ceutical Affairs Law in Japan.
Owing to the introductions of IFN-free regimens of
DAAs, use of IFN is limited to settings in which new
treatments may initially be too expensive to be utilized
[22]. Considering that HCV infection may cause chronic
and morbid liver diseases (i.e., liver cirrhosis or hepato-
cellular carcinoma), such a perspective is acceptable in
general. However, at the same time, we should pay close
attention to the presence or emergence of resistance to
those DAAs. In particular, with the recently approved
simeprevir, up to 40 % of patients in the US infected
with genotype 1a HCV have Q80K mutation before
treatment. Thus, it is strongly recommended this poly-
morphism should be screened prior to treatment with
Table 3 Factors associated with non-sustained virological response to peginterferon-α and ribavirin treatment in chronic hepatitis
C patients
Groups Univariate analysis Multivariate analysis
Factors SVR Non-SVR Coefficient P-value B Odds ratio 95 % C.I.
Gender (Male/Female) 4234/3740 2426/3080 106.402 <0.001 −0.302 0.739 0.683–0.800
Age (≥65 years/<65 years) 1865/6093 2079/3414 325.742 <0.001 −0.392 0.676 0.618–0.739
History of IFN treatment
(naïve/experienced)
6106/1733 3676/1755 172.508 <0.001 −0.407 0.665 0.610–0.726
Genotype (1/2 + 3) 4386/3439 4577/818 1212.744 <0.001 −1.344 0.261 0.238–0.286
Viral load (high/low) 7204/736 5281/182 178.857 <0.001 −1.213 0.297 0.247–0.359
Pre-AST (U/L)* 43 [30–69] (n = 7928) 45 [32–68] (n = 5457) <0.001
Pre-ALT (U/L)* 54 [31–93] (n = 7931) 48 [31–75] (n = 5459) <0.001 0.005 1.005 1.004–1.005




<0.001 0.018 1.019 1.009–1.029




<0.001 −0.164 0.849 0.821–0.877
Year of starting treatment – 2008 3062 2327 Reference
2009 1958 1362 7.949 0.019 −0.085 0.918 0.831–1.015
2010– 2950 1915 −0.095 0.909 0.830–0.997
Region Hokkaido/Tohoku 941 711 −0.288 0.750 0.653–0.861
Kanto 547 316 −0.064 0.938 0.786–1.119
Shin-etsu 361 271 −0.069 0.933 0.765–1.137
Hokuriku 490 354 −0.032 0.969 0.815–1.152
Tokai 557 381 21.777 0.005 −0.069 0.934 0.789–1.105
Kinki 1637 1160 −0.116 0.891 0.790–1.004
Chugoku 1322 920 −0.044 0.957 0.844–1.085
Shikoku 314 257 −0.399 0.671 0.546–0.825
Kyushu 1808 1138 Reference
The values of pre-AST, pre-ALT, pre-PLT, and FIB-4 index are shown as median [interquartile range]
aSince pre-AST and pre-ALT were closely correlated (r = 0.872; P < 0.001), only pre-ALT was included in multivariate analysis. Significant factors by multivariate ana-
lysis are shown in bold. The patients whose treatment outcome could not be determined were excluded from this analysis (n = 576)
ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; C.I., Confidence interval; FIB-4, Fibrosis-4; IFN, Interferon; PLT, Platelets; SVR, Sustained
virological response
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ation for the Study of Liver Diseases/Infectious Diseases
Society of America Recommendations [23]. In addition,
we need to think about the possibility of unexpected
emergence of resistance to various forthcoming DAAs, in
case of patients with poor drug adherence or viral break-
through. The necessity for adequate education of general
physicians, as well as HCV-infected patients, should be
emphasized, for standardized performance and outcome
of the forthcoming treatment, including DAAs.
There were several limitations to this study. First, our
nationwide database consisted of only ~20 % of patients
in the prefectures who benefited from the governmental
subsidy policy, and was not reflective of all patients in
Japan. However, considering that the difference in the
percentage of elderly patients (≥65 years) between our
collected reports and all applicants for this subsidy dur-
ing the initial 3 years in each prefecture was only 1.3 %(median; interquartile range:–2.7 to 4.1 %; preliminary
analysis for 26 prefectures), we may assume that our
database represents all the patients who benefited from
this subsidy policy. Second, the number of collected pa-
rameters was inevitably influenced by the willingness of
the doctors to complete the reports during daily clinical
practice. Thereby, information regarding the doctors’
specialty, drug adherence, or treatment outcome of pre-
viously administered IFN could not be included in this
analysis. Third, generalizability of our findings is neces-
sary, however, it is difficult for this type of large cohort
study for P/R therapy in a rapidly changing era of treat-
ment modalities for CHC. Finally, we were unable to
collect information regarding the accessibility to medical
resources for individual patients, which may have af-
fected treatment accomplishment. Further investigation
would be indispensable to evaluate this issue, by analyz-
ing additional factors in those areas, such as a going-to-
Masaki et al. BMC Public Health  (2015) 15:566 Page 10 of 11hospital time, availability of consultation networks be-
tween base hospitals and local clinics, and so on.Conclusions
Treatment performance and outcome in patients with
CHC are not yet standardized in Japan and further investi-
gations to solve the problems of regional disparities should
be performed from the viewpoint of local clinical practice.
The policies for treatment of hepatitis by the Japanese
government should be formulated to correspond with the
characteristics of the respective jurisdictions so that the
patients with viral hepatitis may receive the highest stand-
ard of medical care, regardless of the locality where
they reside.Additional files
Additional file 1: Figure S1. Correlation between treatment
accomplishment and sustained virological response (SVR) rates in patients
treated by peginterferon-α and ribavirin in nine regions of Japan. SVR
rates were strongly correlated with the rates of treatment accomplishment
(r = 0.879, P = 0.002).
Additional file 2: Figure S2. Rates of severe adverse events (SAE) and
unrelated incidents among the reasons for withdrawal of peginterferon-α
and ribavirin therapy. There was no regional difference among nine
regions of Japan (P = 0.075).
Additional file 3: Figure S3. Rates of poor response to peginterferon-α
and ribavirin (P/R) and other agents as reasons for treatment withdrawal
because of unrelated incidents. The proportion of patients with poor
response to P/R, according to criteria for response-guided therapy
differed among nine regions of Japan (P = 0.019). In Hokkaido/Tohoku
the proportion was the lowest.
Additional file 4: Figure S4. Proportions of elderly patients and
treatment accomplishment rate for peginterferon-α and ribavirin in nine
regions of Japan. No correlation was found between the proportions of
elderly patients and treatment accomplishment rate (r = −0.107, P = 0.783).
Additional file 5: Figure S5. Proportions of elderly patients and
sustained virological response (SVR) rate in patients treated by
peginterferon-α and ribavirin in nine regions of Japan. No correlation
was found between the proportions of elderly patients and SVR rate
(r = 0.133, P = 0.733).
Additional file 6: Figure S6. Numbers of specialists in hepatology and
treatment accomplishment rate in patients treated by peginterferon-α
and ribavirin in nine regions of Japan. No correlation was found between
these two parameters (r = 0.030, P = 0.939).
Additional file 7: Figure S7. Numbers of specialists in hepatology and
sustained virological response (SVR) rate in patients treated by
peginterferon-α and ribavirin in nine regions of Japan. No correlation was
found between these two parameters (r = 0.088, P = 0.822).
Additional file 8: Figure S8. Population density in each region in
Japan. The figures were calculated based on the Basic Resident Register
of Japan in 2013 (http://www.soumu.go.jp/menu_news/s-news/
01gyosei02_02000055.html). In this figure, data for the Hokkaido and
Tohoku regions are shown separately.Abbreviations
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